---
layout: default
title: Acer Negundo Root Bark Amaranthus Hybridus Leaf Am
parent: 僅模型預測 (L5)
nav_order: 71
evidence_level: L5
indication_count: 0
---

# Acer Negundo Root Bark Amaranthus Hybridus Leaf Am
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Allergen Mixture (31 Ingredients): No Repurposing Prediction Available

## One-Sentence Summary

This entry consists of a complex 31-ingredient mixture comprising multiple plant pollens, botanical extracts, biological agents (Corticotropin, Histamine Dihydrochloride, Neurotensin), and animal-derived materials — the composition is consistent with an allergen immunotherapy or allergy diagnostic panel.
The TxGNN pipeline **did not generate any repurposing predictions** for this candidate, most likely because the mixture could not be resolved to a single DrugBank entity.
With **no clinical trials, no publications, and no regulatory approvals** on record, this entry cannot proceed to a meaningful repurposing evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unknown (no regulatory records found) |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; no actual studies |
| US Market Status | Not marketed (no licenses on file) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This candidate (`TW-UNKNOWN-multi`) contains **31 distinct biological and botanical components**, including:

- **Plant pollens**: *Betula occidentalis*, *Populus fremontii*, *Populus tremuloides*, *Quercus kelloggii*, *Pinus ponderosa*, *Chenopodium album*, and others
- **Botanical extracts/whole plants**: *Ambrosia artemisiifolia*, *Amaranthus hybridus*, *Medicago sativa*, *Plantago lanceolata*, *Cynodon dactylon*, *Rumex crispus*, *Xanthium strumarium*, and others
- **Biological agents**: Corticotropin (ACTH), Histamine Dihydrochloride (standard allergy test positive control), Neurotensin
- **Animal-derived materials**: Beef liver, *Sus scrofa* adrenal gland

The TxGNN model operates on single-entity drug nodes mapped to DrugBank IDs. Because this mixture:
1. Has **no DrugBank ID** assigned,
2. Contains **no single active pharmaceutical ingredient** that can be isolated as the repurposing target, and
3. Was not found in any TFDA regulatory database,

the pipeline could not generate a knowledge-graph embedding for prediction. The `predicted_indications` array is empty as a direct consequence.

The composition — allergens alongside histamine and corticotropin — is characteristic of **allergen extract panels used in allergy skin testing or subcutaneous immunotherapy (SCIT)**. Such products are not typically candidates for small-molecule repurposing analysis.

---

## Safety Considerations

No safety data is available through the current pipeline (DDI query returned no results; TFDA package insert data not retrieved). Please refer to the individual component package inserts and standard allergen immunotherapy handling guidelines for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This entry is a multi-component allergen mixture that cannot be processed by the TxGNN single-entity repurposing framework. There are no predicted indications, no regulatory approvals, and no retrievable safety data — making a repurposing evaluation impossible at this stage.

**To proceed, the following is needed:**

- **Identify the repurposing target**: Determine which single active ingredient (e.g., Corticotropin, Neurotensin, or Histamine Dihydrochloride) is the intended focus of repurposing analysis, and re-submit that ingredient as a standalone candidate.
- **Resolve DrugBank mapping**: Assign a DrugBank ID to the target component to enable TxGNN knowledge-graph embedding.
- **Retrieve TFDA/FDA package insert data**: Address Data Gap DG001 by downloading and parsing the relevant product monograph for safety screening (currently Blocking severity).
- **Clarify product category**: Confirm whether this entry represents a marketed allergen immunotherapy product or a diagnostic reagent panel, as these follow different regulatory and repurposing pathways.
- **Re-run pipeline on individual components**: If any of the 31 components (particularly Corticotropin or Neurotensin, which have established pharmacological profiles) is the intended repurposing candidate, submit it as a standalone `candidate_id`.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

